Monoclonal Antibody to Neutrophil gelatinase-associated lipocalin (NGAL)
| Code | Size | Price |
|---|
| MAB388Ra23-20ul | 20uL | £93.00 |
Quantity:
| MAB388Ra23-100ul | 100ul | £176.00 |
Quantity:
| MAB388Ra23-200ul | 200ul | £238.00 |
Quantity:
| MAB388Ra23-1ml | 1ml | £549.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Antibody Clone: D6
Regulatory Status: RUO
Target Species: Rat
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Further Information
Alternative Names:
Lipocalin-2; LCN2; p25; Lipocalin 2; Oncogene 24p3; 25 kDa alpha-2-microglobulin-related subunit of MMP-9; Siderocalin LCN2
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Neutrophil gelatinase-associated lipocalin
Potency (Clone Number):
D6
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.2-2ug/mL;1:500-5000
Immunohistochemistry: 5-20ug/mL;1:50-200
Immunocytochemistry: 5-20ug/mL;1:50-200
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;1:50-200
Immunocytochemistry: 5-20ug/mL;1:50-200
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Neutrophil Gelatinase Associated Lipocalin (NGAL) | RPB388Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||